Beacon Therapeutics

About Beacon Therapeutics

Beacon Therapeutics develops AAV gene therapy to treat blinding retinal diseases, including X-Linked Retinitis Pigmentosa, by introducing functional copies of mutated genes into patients' cells. This approach aims to restore vision and improve the quality of life for individuals affected by these conditions.

```xml <problem> Inherited retinal diseases, such as X-Linked Retinitis Pigmentosa, lead to progressive vision loss and blindness due to mutated genes within retinal cells. Current treatments offer limited efficacy, and many patients face a decline in their quality of life as their vision deteriorates. </problem> <solution> Beacon Therapeutics is developing adeno-associated virus (AAV) gene therapies designed to address the underlying genetic causes of inherited retinal diseases. Their approach involves introducing functional copies of mutated genes into patients' retinal cells, enabling the body to produce proteins necessary for proper retinal function. By targeting the root cause of these diseases, Beacon Therapeutics aims to restore vision and provide long-lasting benefits with a single treatment. The company's lead program focuses on X-Linked Retinitis Pigmentosa (XLRP) and is currently in Phase 2/3 clinical trials. Beacon Therapeutics is also developing gene therapies for Dry Age-related Macular Degeneration (dAMD) and Cone Rod Dystrophy (CRD). </solution> <features> - AAV-based gene therapy platform for targeted delivery of functional genes to retinal cells - Clinical-stage program (VISTA trial) for X-Linked Retinitis Pigmentosa (XLRP) - Investigational therapies for Dry Age-related Macular Degeneration (dAMD) and Cone Rod Dystrophy (CRD) - Utilizes a single treatment approach to provide long-lasting benefits - Aims to restore vision and improve the quality of life for patients with inherited retinal diseases </features> <target_audience> The primary target audience includes patients diagnosed with inherited retinal diseases, such as X-Linked Retinitis Pigmentosa, Dry Age-related Macular Degeneration, and Cone Rod Dystrophy, as well as their caregivers and healthcare providers specializing in ophthalmology and gene therapy. </target_audience> ```

What does Beacon Therapeutics do?

Beacon Therapeutics develops AAV gene therapy to treat blinding retinal diseases, including X-Linked Retinitis Pigmentosa, by introducing functional copies of mutated genes into patients' cells. This approach aims to restore vision and improve the quality of life for individuals affected by these conditions.

Where is Beacon Therapeutics located?

Beacon Therapeutics is based in London, United Kingdom.

When was Beacon Therapeutics founded?

Beacon Therapeutics was founded in 2023.

Who founded Beacon Therapeutics?

Beacon Therapeutics was founded by Lance Baldo.

  • Lance Baldo - CEO
Location
London, United Kingdom
Founded
2023
Employees
77 employees
Looking for specific startups?
Try our free semantic startup search

Beacon Therapeutics

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Beacon Therapeutics develops AAV gene therapy to treat blinding retinal diseases, including X-Linked Retinitis Pigmentosa, by introducing functional copies of mutated genes into patients' cells. This approach aims to restore vision and improve the quality of life for individuals affected by these conditions.

beacontx.com5K+
Founded 2023 – London, United Kingdom

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (75+)

Lance Baldo

CEO

Company Description

Problem

Inherited retinal diseases, such as X-Linked Retinitis Pigmentosa, lead to progressive vision loss and blindness due to mutated genes within retinal cells. Current treatments offer limited efficacy, and many patients face a decline in their quality of life as their vision deteriorates.

Solution

Beacon Therapeutics is developing adeno-associated virus (AAV) gene therapies designed to address the underlying genetic causes of inherited retinal diseases. Their approach involves introducing functional copies of mutated genes into patients' retinal cells, enabling the body to produce proteins necessary for proper retinal function. By targeting the root cause of these diseases, Beacon Therapeutics aims to restore vision and provide long-lasting benefits with a single treatment. The company's lead program focuses on X-Linked Retinitis Pigmentosa (XLRP) and is currently in Phase 2/3 clinical trials. Beacon Therapeutics is also developing gene therapies for Dry Age-related Macular Degeneration (dAMD) and Cone Rod Dystrophy (CRD).

Features

AAV-based gene therapy platform for targeted delivery of functional genes to retinal cells

Clinical-stage program (VISTA trial) for X-Linked Retinitis Pigmentosa (XLRP)

Investigational therapies for Dry Age-related Macular Degeneration (dAMD) and Cone Rod Dystrophy (CRD)

Utilizes a single treatment approach to provide long-lasting benefits

Aims to restore vision and improve the quality of life for patients with inherited retinal diseases

Target Audience

The primary target audience includes patients diagnosed with inherited retinal diseases, such as X-Linked Retinitis Pigmentosa, Dry Age-related Macular Degeneration, and Cone Rod Dystrophy, as well as their caregivers and healthcare providers specializing in ophthalmology and gene therapy.